Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
First of its kind screening for Glaucoma at grass root level over 10k screened already
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Subscribe To Our Newsletter & Stay Updated
